Bharat Biotech prepares master plan for Konark Knowledge park

Details

Category: Bio Pharmaceuticals

Bharat Biotech International Ltd, a Hyderabad based company is joining hands with state government of Orissa to develop the Konark Knowledge park in Andharua in the outskirts of city Bhubansehwar. The park will have a biotech incubation centre spread over 10 acres and will have Rs.250 million from Centre towards incubation and is likely to emerge as centre of excellence. Currently, Bharat Biotech is preparing the master plan, while IDCOL will set up the infrastructure needed for the park like roads, water supply and electricity.

Zydus to set up new unit in Ahmedabad

Details

Category: Bio Pharmaceuticals

Zydus is setting up a new unit in its special economic zone (SEZ) near Ahmedabad with an investment of Rs.1000 million. It will manufacture of transdermal patches and various injectables.  Few years back, the company had launched country’s first indigenously-manufactured diclofenac transdermal patch for pain relief and it is increasingly accepted in US. NuPatch contains 100 mg of diclofenac, a painkiller. Instead of the thrice-a-day dosage as in the case of the oral dosage form, NuPatch needs to be applied just once in a day and provides extended pain relief. The overseas market for transdermal patches is estimated at USD 5 billion as compared to the Indian market ,which is pegged at around Rs 1000 million.

Lonza Group to set up a bio pharma unit at Genome Valley

Details

Category: Bio Pharmaceuticals

Lonza Group, a Basel-based bio-pharmaceutical major is planning to set up its facility in the Genome Valley (Bio SEZ) in Hyderabad with an investment of USD $150 million.

Kemwell ties up with Boehringer to set up biopharma plant in Bangalore

Details

Category: Bio Pharmaceuticals

Kemwell, a provider of contract manufacturing and development services for pharmaceutical products globally, is building a biopharmaceutical manufacturing plant in Bangalore with an investment of Rs 2350 million. It has tied up with German pharmaceutical firm Boehringer Ingelheim for technical and marketing collaboration. It will be a 15,000 sq mt greenfield facility,being designed for process development, fermentation, purification and formulation of biologicals for clinical studies. The plant will consist of a cGMP (current Good Manufacturing Practices)-compliant drug manufacturing facility and, a sterile fill and finish facility for drugs. It will house process development laboratories to support production of protein therapeutics.